FAETH THERAPEUTICS INC
FTHNASDAQ🏆 #2725 by market capUS Equity
$28.08▲ $0.32 (+1.13%)
After hours · at closeTrack FTH
Get earnings, price moves & breaking news on Telegram
24h▲ 1.1%
7d▼ 15.6%
14d▼ 20.9%
30d▼ 16.7%
ytd▲ 165.1%
1y▲ 229.9%
🏦Market Cap
$724M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
2740.8%
High
💵FCF Margin
698.0%
Strong
⚖️P/S Ratio
-147.6x
Cheap
Otter Score
76
Good
Trading Snapshot
- Day Range
- $27.66 – $28.43
- 52-Week Range
- $7.45 – $42.14
- Volume
- $2.05B
- Avg Volume
- $2.43B
- Shares Outstanding
- 25.8M
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $85M
- Last Q Revenue
- $22M
- P/E Ratio
- -0.2
- P/S Ratio
- -147.6x
- EPS (TTM)
- $-34.65
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.3%
Why Investors Own FTH
- ✓High-growth profile — revenue up +18.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FAETH THERAPEUTICS INC
FTHFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −29.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▼ −17.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.3M▲ +0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$1M YoY
StockOtter · stockotter.spaceAbout FAETH THERAPEUTICS INC
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100
Analyst Price Target
ⓘAverage Target
$31.61
▲ +12.6% Upside
High Target$34.42
Low Target$26.44
Based on 16 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
FAETH THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift FTH price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
FAETH THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.